1. Home
  2. BGMS vs JAGX Comparison

BGMS vs JAGX Comparison

Compare BGMS & JAGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bio Green Med Solution Inc.

BGMS

Bio Green Med Solution Inc.

N/A

Current Price

$1.03

Market Cap

5.0M

Sector

N/A

ML Signal

N/A

Logo Jaguar Health Inc.

JAGX

Jaguar Health Inc.

HOLD

Current Price

$0.41

Market Cap

5.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BGMS
JAGX
Founded
1996
2013
Country
Malaysia
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.0M
5.0M
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
BGMS
JAGX
Price
$1.03
$0.41
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$60.00
AVG Volume (30 Days)
81.4K
367.8K
Earning Date
05-14-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$11,689,000.00
Revenue This Year
$137.21
$22.41
Revenue Next Year
N/A
$30.00
P/E Ratio
N/A
N/A
Revenue Growth
N/A
19.75
52 Week Low
$0.73
$0.31
52 Week High
$6.70
$15.48

Technical Indicators

Market Signals
Indicator
BGMS
JAGX
Relative Strength Index (RSI) 49.85 41.38
Support Level $0.74 N/A
Resistance Level $1.13 $0.69
Average True Range (ATR) 0.10 0.04
MACD 0.01 0.01
Stochastic Oscillator 49.84 43.75

Price Performance

Historical Comparison
BGMS
JAGX

About BGMS Bio Green Med Solution Inc.

Bio Green Med Solution Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib and plogosertib. The company derives its revenue from United Kingdoms.

About JAGX Jaguar Health Inc.

Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.

Share on Social Networks: